{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:17:02Z","timestamp":1788261422962,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81370548"],"award-info":[{"award-number":["81370548"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.prostaglandins.2017.08.004","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T13:15:32Z","timestamp":1502889332000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis"],"prefix":"10.1016","volume":"131","author":[{"given":"Wensheng","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 Suppl","key":"10.1016\/j.prostaglandins.2017.08.004_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(00)80422-5","article-title":"Complications of cirrhosis. I. Portal hypertension","volume":"32","author":"Bosch","year":"2000","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","article-title":"Functional aspects on the pathophysiology of portal hypertension in cirrhosis","volume":"57","author":"Garcia-Pagan","year":"2012","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.08.004_bib0015","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2010.03.021","article-title":"Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension","volume":"53","author":"Bosch","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","article-title":"Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health","volume":"53","author":"Morisseau","year":"2013","journal-title":"Annu. Rev. Pharmacool. Toxicol."},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/mol.114.097501","article-title":"Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental acute pancreatitis in mice","volume":"88","author":"Bettaieb","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HJH.0b013e32835b50aa","article-title":"Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME","volume":"31","author":"Honetschlagerova","year":"2013","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0035","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000445663","article-title":"CYP2J2-derived EETs attenuated angiotensin II-induced adventitial remodeling via reduced inflammatory response","volume":"39","author":"Zhou","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"issue":"10","key":"10.1016\/j.prostaglandins.2017.08.004_bib0040","doi-asserted-by":"crossref","first-page":"e110162","DOI":"10.1371\/journal.pone.0110162","article-title":"The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease","volume":"9","author":"Schuck","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0045","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1152\/ajpendo.00366.2014","article-title":"CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice","volume":"308","author":"Chen","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.taap.2015.03.022","article-title":"Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice","volume":"286","author":"Harris","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0016-5085(98)70487-1","article-title":"Chung JJ.;1;: Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension","volume":"114","author":"Rockey","year":"1998","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.prostaglandins.2017.08.004_bib0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/ATVBAHA.108.171298","article-title":"Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice","volume":"29","author":"Hercule","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1073\/pnas.1422590112","article-title":"Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides","volume":"112","author":"Lopez-Vicario","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.prostaglandins.2017.08.004_bib0070","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.3748\/wjg.v22.i18.4484","article-title":"Role of estrogen receptor beta selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis","volume":"22","author":"Zhang","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.prostaglandins.2017.08.004_bib0075","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gut.2010.226407","article-title":"Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction","volume":"60","author":"Moleda","year":"2011","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.08.004_bib0080","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2012.12.012","article-title":"Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats","volume":"58","author":"Di Pascoli","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2017.03.007","article-title":"Inhibition of soluble epoxide hydrolase reduces portal pressure by protecting mesenteric artery myogenic responses in cirrhotic rats","author":"Huang","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"4","key":"10.1016\/j.prostaglandins.2017.08.004_bib0090","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.27343","article-title":"Molecular pathophysiology of portal hypertension","volume":"61","author":"Fernandez","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"8","key":"10.1016\/j.prostaglandins.2017.08.004_bib0095","doi-asserted-by":"crossref","first-page":"H1146","DOI":"10.1152\/ajpheart.00920.2013","article-title":"Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure","volume":"306","author":"Sun","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20110622","article-title":"Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension","volume":"11","author":"Neckar","year":"2012","journal-title":"Clin. Sci. (London, England : 1979)"},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.08.004_bib0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1034\/j.1600-0676.2002.01588.x","article-title":"Enhanced expression of endothelial nitric oxide synthase and caveolin-1 in human cirrhosis","volume":"22","author":"Yokomori","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0115","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ajpath.2016.11.017","article-title":"Caveolin 1 and G-protein-coupled receptor kinase-2 coregulate endothelial nitric oxide synthase activity in sinusoidal endothelial cells","volume":"4","author":"Liu","year":"2017","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.08.004_bib0120","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.bjp.0702171","article-title":"Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome p450-derived arachidonate metabolites","volume":"125","author":"Oyekan","year":"1998","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2017.08.004_bib0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1748-1716.2010.02222.x","article-title":"Interaction of nitric oxide and the cytochrome P-450 system on blood pressure and renal function in the rat: dependence on sodium intake","volume":"201","author":"Kuczeriszka","year":"2011","journal-title":"Acta Physiol. (Oxford, England)"},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1475-2840-10-114","article-title":"CYP2J3 gene delivery reduces insulin resistance via upregulation of eNOS in fructose-treated rats","volume":"10","author":"Xu","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0135","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/HYPERTENSIONAHA.114.03884","article-title":"CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype","volume":"6","author":"Abraham","year":"2014","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"issue":"1 Suppl","key":"10.1016\/j.prostaglandins.2017.08.004_bib0140","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.prostaglandins.2017.08.004_bib0145","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1042\/CS20090549","article-title":"Role of nuclear factor kappaB in liver health and disease","volume":"12","author":"Robinson","year":"2010","journal-title":"Clin. Sci. (London, England : 1979)"},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.08.004_bib0150","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","article-title":"Shared principles in NF-kappaB signaling","volume":"132","author":"Hayden","year":"2008","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.08.004_bib0155","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.28686","article-title":"Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation","volume":"64","author":"Di Pascoli","year":"2016","journal-title":"Hepatology (Baltimore, Md)"}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882317300801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882317300801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T09:53:01Z","timestamp":1535449981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882317300801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":31,"alternative-id":["S1098882317300801"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2017.08.004","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2017.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}